Jerusalem, 8 January, 2026 (TPS-IL) — Israel-based Cytora Therapeutics has partnered with two U.S. companies to manufacture and commercialize its allogeneic stem cell therapy in the United States, targeting non-healing diabetic foot ulcers and other indications.
Under the agreement, Made Scientific, a U.S. cell therapy CDMO headquartered in New Jersey, will serve as the exclusive U.S. manufacturing partner, while Florida-based Zeo ScientifiX will lead commercialization and market access. The collaboration will initially pursue commercialization in Florida under the state’s recently enacted stem cell access law, while advancing parallel U.S. FDA Phase 2b clinical trials.
Cytora will continue overseeing clinical and regulatory development from Israel.